Compare MP & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MP | CRL |
|---|---|---|
| Founded | 2017 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 8.0B |
| IPO Year | N/A | 2000 |
| Metric | MP | CRL |
|---|---|---|
| Price | $65.38 | $218.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 14 |
| Target Price | $70.92 | ★ $193.17 |
| AVG Volume (30 Days) | ★ 6.7M | 626.8K |
| Earning Date | 02-19-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $232,742,000.00 | ★ $4,023,704,000.00 |
| Revenue This Year | $36.77 | N/A |
| Revenue Next Year | $145.71 | $1.68 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 26.44 | N/A |
| 52 Week Low | $18.64 | $91.86 |
| 52 Week High | $100.25 | $222.37 |
| Indicator | MP | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 64.80 | 73.39 |
| Support Level | $59.35 | $208.67 |
| Resistance Level | $65.55 | $222.37 |
| Average True Range (ATR) | 2.91 | 5.37 |
| MACD | 1.52 | 1.10 |
| Stochastic Oscillator | 90.60 | 87.24 |
MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America. The company is also developing a rare earth metal, alloy, and magnet manufacturing facility in Fort Worth, Texas. The company's operations are organized into two reportable segments: Materials and Magnetics.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.